Chinese, drug-naive patients, who were within 20 to 90 years old, newly diagnosed with T2DM and have an HbA1c level of <10.0%, were randomized (2:1) to receive either repaglinide (n = 40, M/F 21/19) or metformin (n = 20, M/F 16/4) monotherapy. None of these subjects had a history of coronary heart disease, abnormal renal function, active liver disease, unstable angina, alcohol or drug abuse, chronic or severe metabolic acidosis, or chronic gastrointestinal disease.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.
Tips for asking effective questions
+ Description
Write a detailed description. Include all information that will help others answer your question including experimental processes, conditions, and relevant images.